Strados Labs Acquires NuvoAir Clinical Trials Unit to Expand Respiratory Endpoint Platform

With the acquisition, Strados Labs now offers a combined respiratory endpoint suite that includes continuous cough monitoring, lung sound analysis, pulmonary function testing, airway inflammation measurement, and patient-reported outcomes.

Strados Labs has acquired the clinical trial division of NuvoAir Inc., strengthening its position in respiratory clinical research by expanding its endpoint measurement capabilities for pharmaceutical and biotech companies.

The transaction, which closed in March 2026, brings NuvoAir Clinical Trials under Strados Labs’ portfolio and adds remote and in-clinic spirometry, fractional exhaled nitric oxide (FeNO) testing, and electronic clinical outcome assessments (eCOA) to its existing respiratory monitoring technologies.

With the acquisition, Strados Labs now offers a combined respiratory endpoint suite that includes continuous cough monitoring, lung sound analysis, pulmonary function testing, airway inflammation measurement, and patient-reported outcomes. The platform is designed to support respiratory clinical trials across all phases, from Phase I through Phase IV.

The integrated system combines Strados’ RESP® Biosensor and RESP® Watch with NuvoAir’s spirometry technology, along with FeNO measurement tools and digital outcome reporting systems. The company said the unified platform allows sponsors and clinical research organizations (CROs) to access multiple respiratory endpoints through a single provider and integration process.

Strados Labs stated that the combined offering is intended to address increasing demand in respiratory drug development for continuous and real-world patient data beyond traditional clinic-based assessments. The system also includes AI-supported analysis for cough detection and lung sound monitoring, along with compliance-focused spirometry workflows aligned with clinical standards.

The RESP® Biosensor, which has received two FDA 510(k) clearances and CE marking, has already been deployed across more than 55 clinical trials globally. These studies span conditions such as chronic obstructive pulmonary disease (COPD), asthma, idiopathic pulmonary fibrosis (IPF), cystic fibrosis, and chronic cough.

Strados Labs CEO Nick Delmonico said the combined platform is intended to support more complete respiratory data collection across clinical settings, while maintaining regulatory-grade data quality.

NuvoAir CEO Chris Skowronek said the acquisition allows its clinical trial division to expand through Strados Labs while the company continues focusing on patient care services.

Strados Labs confirmed that existing NuvoAir clinical trial programs will continue without disruption, with ongoing access to operational teams and platform services.

Stay tuned for more such updates on Digital Health News